ReviewPharmaceutics2022
Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Nanoparticle Platforms in Cancer Immunotherapy: A Critical Comparative Review of PLGA, Mesoporous Silica, Magnetic Nanoparticles, and Covalent Organic Frameworks.Pharmaceutics · 2026Review
- S1-4 aptamer-mediated iron oxide nanoparticles for targeted magnetic hyperthermia in MCF-7 breast cancer cells.The Journal of international medical research · 2026Article
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Application of magnetic resonance spectroscopy (MRS) in photo-thermal therapy response of U87-MG human glioma cells with gold-coated iron oxide nanoparticles: an in vivo study.Magma (New York, N.Y.) · 2026Article
- Analysis of the Feasibility of Concurrent Application of Magnetic Nanoparticles as MRI Contrast Agents and for Magnetic Hyperthermia.Journal of functional biomaterials · 2026Article
- Magnetic thermoradiotherapy for lung cancer: evaluation in A549-based preclinical models.Frontiers in oncology · 2026Article
- Advancements in Superparamagnetic Iron Oxide Nanoparticles for Magnetic Hyperthermia as a Promising Strategy to Combat Antibacterial Resistance.International journal of nanomedicine · 2026Review
- Aptamers and aptamer-drug conjugates as synthetic immune modulators for cancer immunotherapy.Frontiers in immunology · 2026Review
- Modular Flow Synthesis of Citric Acid-Coated Superparamagnetic Iron Oxide Nanoparticles: Preliminary Results.Micromachines · 2025Article
- Recent advances in metallic nanostructure-based photothermal therapy in the management of cancer metastasis.Medical oncology (Northwood, London, England) · 2025Review
- Application of Biomimetic SPIONs in Targeted Lung Cancer Therapy: Cell-Membrane Camouflage Technology and Lung Retention Enhancement Strategies.Pharmaceutics · 2025Review
- A New Nanotechnology for Imaging the Juxta-Articular Intraosseous Vasculature-Canal Complex and Related Clinical Pilot Studies.Orthopaedic surgery · 2025Article
- Impedance Analysis of a Two-Layer Air-Core Coil for AC Magnetometry Applications.Sensors (Basel, Switzerland) · 2025Article
- Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry.Pharmaceutics · 2025Review
- Recent Advancement in MRI-Based Nanotheranostic Agents for Tumor Diagnosis and Therapy Integration.International journal of nanomedicine · 2025Review
- Evaluation of Self-Regulating Doped Ferrite Nanoparticles with Glucose, Chitosan, and Poly-Ethylene Glycol Coatings for Hyperthermia and Dual Imaging.International journal of nanomedicine · 2025Article
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy.Biomarker research · 2024Review
- Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert "Cold" Tumors to "Hot" Tumors.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Cancer immunotherapy has tremendous promise, but it has yet to be clinically applied in a wider variety of tumor situations. Many therapeutic combinations are envisaged to improve their effectiveness. In this way, strategies capable of inducing immunogenic cell death (e.g., doxorubicin, radiotherapy, hyperthermia) and the reprogramming of the immunosuppressive tumor microenvironment (TME) (e.g., M2-to-M1-like macrophages repolarization of tumor-associated macrophages (TAMs)) are particularly appealing to enhance the efficacy of approved immunotherapies (e.g., immune checkpoint inhibitors, ICIs). Due to their modular construction and versatility, iron oxide-based nanomedicines such as superparamagnetic iron oxide nanoparticles (SPIONs) can combine these different approaches in a single agent. SPIONs have already shown their safety and biocompatibility and possess both drug-delivery (e.g., chemotherapy, ICIs) and magnetic capabilities (e.g., magnetic hyperthermia (MHT), magnetic resonance imaging). In this review, we will discuss the multiple applications of SPIONs in cancer immunotherapy, focusing on their theranostic properties to target TAMs and to generate MHT. The first section of this review will briefly describe immune targets for NPs. The following sections will deal with the overall properties of SPIONs (including MHT). The last section is dedicated to the SPION-induced immune response through its effects on TAMs and MHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.